Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
tolterodine
|
| gptkbp:availableFormats |
brand
generic |
| gptkbp:brand |
gptkb:Detrol
|
| gptkbp:clinicalTrials |
studies on efficacy
studies on safety management of bladder control issues not recommended for certain heart conditions recommended for overactive bladder treatment of urinary incontinence |
| gptkbp:contraindication |
fatigue
headache nausea dry eyes stomach pain urinary retention gastric retention narrow-angle glaucoma |
| gptkbp:date |
2000-11-01
|
| gptkbp:dosageForm |
2 mg or 4 mg
|
| gptkbp:drugInterdiction |
alcohol
prescription only anticholinergic drugs CYP2D6 inhibitors |
| gptkbp:endOfLife |
3 to 4 hours
|
| gptkbp:formulation |
extended-release capsule
|
| gptkbp:gestationPeriod |
Category C
|
| gptkbp:hasPopulation |
adults
elderly |
| gptkbp:healthcare |
stay hydrated
do not drive if dizzy report severe side effects |
| https://www.w3.org/2000/01/rdf-schema#label |
Detrol LA
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:United_States Europe |
| gptkbp:nutritionalValue |
liver
|
| gptkbp:packaging |
blister pack
|
| gptkbp:relatedPatent |
urge incontinence
bladder dysfunction |
| gptkbp:researchFocus |
patient adherence
long-term effects quality of life improvements comparative effectiveness |
| gptkbp:route |
oral
|
| gptkbp:sideEffect |
dizziness
constipation dry mouth blurred vision |
| gptkbp:storage |
room temperature
|
| gptkbp:usedFor |
overactive bladder
|
| gptkbp:waterManagement |
urine
|